tbuckley/cabot-search huggingface dataset:
OP0102 INTERVERTEBRAL DISC THERAPIES FOR NON-SPECIFIC CHRONIC LOW BACK PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Camille Daste, Stéphanie Laclau, Margaux Boisson, François Segretin, Antoine Feydy, Marie-Martine Lefevre Colau, François Rannou, Christelle Nguyen
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Intervertebral disc therapies (IDT) for the management of non-specific chronic low back (NScLBP) pain are raising interest (1). <h3>Objectives</h3> To review evidence on the benefits and harms of IDT in people with NScLBP. <h3>Methods</h3> We searched 4 databases and conference abstracts, from inception to July 2018, for randomized trials of IDT <i>versus</i> placebo interventions, active comparators or usual care. Two independent investigators extracted data and assessed the risk of bias. The primary outcome was LBP intensity at short, intermediate and long terms (2). Secondary outcomes were LBP-specific activity limitation and safety (3). Our review was registered with the International Prospective Register of Systematic Reviews (CRD42019106336). <h3>Results</h3> Of 17 eligible trials, 5 trials (436 patients) assessed glucocorticoid (GC) IDT and were included in a quantitative synthesis. Twelve trials assessed IDT of other products including ozone (n=2, 140 patients), methylene blue (n=1, 72 patients), stems cells (n=1, 24 patients), glycerol (n=1, 11 patients), etanercept (n=2, 96 patients), tocilizumab (n=1, 60 patients), platelet-rich plasma (n=1, 47 patients), chymopapaine (n=1, 39 patients) and rhGDF-5 (n=2, 55 patients) and were included in a narrative synthesis. Standardized mean differences (SMD) of GC IDT for LBP intensity and activity limitations were -1.33 (-2.34;-0.32) and -0.76 (-1.85;0.34) at short-term, -2.22 (-5.34;0.90) and -1.60 (-3.51;0.32) at intermediate-term and -1.11 (-2.91;0.70) and -0.63 (-1.68;0.42) at long-term, respectively. OR of GC IDT for serious and minor adverse events were 1.13 (0.20; 4.59) and 0.97 (0.49;1.91). <h3>Conclusion</h3> GC IDT are associated with a reduction in LBP intensity at short-term in people with NScLBP. Positive effects are not sustained. There is no effect on activity limitations. <h3>References</h3> [1] Knezevic NN, Mandalia S, Raasch J, Knezevic I, Candido KD. Treatment of chronic low back pain - new approaches on the horizon. J Pain Res. 2017;10:1111-23. [2] Chiarotto A, Boers M, Deyo RA, Buchbinder R, Corbin TP, Costa LOP, et al. Core outcome measurement instruments for clinical trials in nonspecific low back pain. Pain. 2018;159(3):481-95. [3] Team QAaSM. Safety of medicines : a guide to detecting and reporting adverse drug reactions : why health professionals need to take action. In: Organization WH, ed. Geneva; 2002. <h3>Disclosure of Interests</h3> None declared
Chronic lymphocytic leukemia
Authors: Tadeusz Robak
Journal: HemaSphere (2019)

Learning goals Get knowledge of the growing importance of molecular genetics providing evidence for inherited susceptibility to CLL and risk of sporadic disease. To understand the mechanisms of acquired clinical resistance in patients treated with novel targeted drugs, particular with ibrutinib, idelalisib, and venetoclax. To learn that many new combination therapies with targeted drugs, monoclonal anti-CD20 antibodies and chemotherapy will improve the outcome of the standard of care for CLL. Introduction Chronic lymphocytic leukemia (CLL) is the most common forms of adult leukemia in the Western world, and is typically diagnosed at 70 years. This is an exciting era in CLL biology, particularly for its understanding, prognostic classification and novel treatment approaches. This educational session will review recent developments in the biology and treatment of CLL. In the first talk, Dr Philip J Law and Dr Richard S Houlston from the Institute of Cancer Research, Sutton (UK) will review the familial risks of CLL. They will discuss the genome-wide association studies (GWAS) that identified the single nucleotide polymorphisms (SNPs) at 43 genetic regions influencing the risk of sporadic CLL. Therapeutic strategies are changing rapidly with the introduction of newer drugs, most of which are orally available, and which are more effective and better tolerated than previously-available therapies. Two of the leading agents now used in the treatment of CLL are ibrutinib and venetoclax. Although these newer agents have improved the prognosis of CLL, particularly in older patients and patients with high-risk genetics, especially those with del 17p/TP53 mutation and unmutated immunoglobulin variable region heavy chain (IGHV), resistant cases are sometimes observed and treatment is often discontinued due to disease progression. In the second lecture, Dr LA Sutton from the Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm (Sweden) will review the mechanism of resistance to novel antileukemic agents used in CLL. Finally, Dr Iris de Weerdt and Dr Arnon P Kater from the University of Amsterdam (the Netherlands) will review new treatment approaches, particularly combination therapies including chemotherapy-free regimens, in previously-untreated and refractory/relapsed patients with CLL in 2019. The results of recent trials clearly demonstrate improved progression-free survival, and sometimes overall survival, associated with the use of new targeted drugs, as single agents or in combination with anti-CD20 monoclonal antibodies, compared with chemoimmunotherapy.
Abstract 11744: The Association Between Plasma Levels of Anti-angiogenic Isoform of Vascular Endothelial Growth Factor and Clinical Profiles of Peripheral Artery Disease
Authors: Akihiko Sato, Akiomi Yoshihisa, Yuki Kanno, Mai Takiguchi, Shunsuke Miura, Takeshi Shimizu, Yuichi Nakamura, Hiroyuki Yamauchi, Takashi Owada, Satoshi Abe, Satoshi Suzuki, Masayoshi Oikawa, Nobuo Sakamoto, Takayoshi Yamaki, Koichi Sugimoto, Hiroyuki Kunii, Kazuhiko Nakazato, Hitoshi Suzuki, Shu-ichi Saitoh, Yasuchika Takeishi
Journal: Circulation (2015)

Background: Although circulating levels of vascular endothelial growth factor (VEGF), known as a stimulator of angiogenesis, were elevated in peripheral artery disease (PAD), patients with PAD is often associated with poor collateral formation, resulting in critical limb ischemia. Recently, it has been reported that VEGF165b, a major splicing variant of human VEGF-A, inhibits angiogenesis in some types of cancer and acts as anti-angiogenic. However, the association between circulating levels of VEGF165b and clinical manifestation of patients with PAD has not been fully examined. Methods and Results: This study included 45 patients with PAD who received endovascular therapy and 20 control subjects without PAD in our hospital. PAD was diagnosed according to the PAD management guidelines, such as computed tomography, angiography, and/or ankle-brachial index. We excluded patients with malignancy, end-stage renal disease on dialysis, severe chronic respiratory failure, and active inflammatory disease in consideration of influence on concentrations of VEGF. We measured circulating concentrations of VEGF165b in peripheral blood samples using enzyme-linked immunosorbent assay (ELISA). Plasma levels of VEGF165b were significantly higher in the PAD group than in the control group (91.7 ± 47.8 pg/ml vs. 30.4 ± 18.3 pg/ml, P&lt;0.001). There was no association between the plasma levels of VEGF165b and the symptom grade (Fontaine class), ankle-brachial index and the lesion morphology based on angiographical findings (TASC-II classification, presence of below knee lesion or chronic total occlusion lesion) in PAD group. In the multiple regression analysis, the independent factors to determine plasma levels of VEGF165b were age (ß 0.258, P=0.031), presence of PAD (ß 0.587, P&lt;0.001), hypertension (ß 0.295, P=0.013), dyslipidemia (ß 0.385, P=0.001), history of stroke (ß 0.245, P=0.041), and coronary artery disease (ß 0.292, P=0.016). Conclusion: Plasma levels of VEGF165b was elevated in PAD, but there was no association between the severity of PAD and levels of VEGF165b. VEGF165b was related to age, hypertension, dyslipidemia, history of cerebral and coronary artery disease as well as PAD.
DNA Methylation Changes in the Sperm of Captive-Reared Fish: A Route to Epigenetic Introgression in Wild Populations
Authors: Deiene Rodriguez Barreto, Carlos Garcia de Leaniz, Eric Verspoor, Halina Sobolewska, Mark Coulson, Sofia Consuegra
Journal: Molecular Biology and Evolution (2019)

Interbreeding between hatchery-reared and wild fish, through deliberate stocking or escapes from fish farms, can result in rapid phenotypic and gene expression changes in hybrids, but the underlying mechanisms are unknown. We assessed if one generation of captive breeding was sufficient to generate inter- and/or transgenerational epigenetic modifications in Atlantic salmon. We found that the sperm of wild and captive-reared males differed in methylated regions consistent with early epigenetic signatures of domestication. Some of the epigenetic marks that differed between hatchery and wild males affected genes related to transcription, neural development, olfaction, and aggression, and were maintained in the offspring beyond developmental reprogramming. Our findings suggest that rearing in captivity may trigger epigenetic modifications in the sperm of hatchery fish that could explain the rapid phenotypic and genetic changes observed among hybrid fish. Epigenetic introgression via fish sperm represents a previously unappreciated mechanism that could compromise locally adapted fish populations.
SP0146 BENEFITS OF CANNABIS TO YOUR JOINTS: HYPE OR HOPE?
Authors: Serge Perrot
Journal: Annals of the Rheumatic Diseases (2019)

<h3></h3> Cannabis-based medicines have been approved for pain management in a number of countries. However, there are uncertainties and controversies about their role and the appropriate use of these medicines for the management of chronic pain, particularly in musculoskeletal conditions. These ancient drugs are now being rediscovered and considered as modern analgesic approaches in the context of cannabis legalization in more and more countries. The fight for cannabis legalization is frequently confused with the search for new analgesics in a medical context. Furthermore, there is a confusion between herbal cannabis, medical cannabis and cannabinoids. Therefore, it is important to differentiate products and situations and look beyond prejudice and misconceptions, to discover whether there are pharmacological and clinical data to support the use of medical cannabis and cannabinoids in musculoskeletal conditions and arthritis. Aside from media and social discussions, we will try to answer to the current hot question for a clinician is "Is it possible to recommend medical cannabis as a new analgesic option in musculoskeletal conditions?" <h3>Disclosure of Interests:</h3> None declared
The intestinal microbiota predisposes to traveler’s diarrhea and to the carriage of multidrug-resistant Enterobacteriaceae after traveling to tropical regions
Authors: Stefano Leo, Vladimir Lazarevic, Nadia Gaïa, Candice Estellat, Myriam Girard, Sophie Matheron, Laurence Armand-Lefèvre, Antoine Andremont, Jacques Schrenzel, Etienne Ruppé
Journal: Gut Microbes (2019)

The risk of acquisition of multidrug-resistant Enterobacteriaceae (MRE) and of occurrence of diarrhea is high when traveling to tropical regions. The relationships between these phenomena and the composition of human gut microbiota have not yet been assessed. Here, we investigated the dynamics of changes of metabolically active microbiota by sequencing total RNA from fecal samples taken before and after travel to tropical regions. We included 43 subjects who could provide fecal samples before and after a travel to tropical regions. When found positive by culturing for any MRE after travel, the subjects sent an additional sample 1 month later. In all, 104 fecal samples were considered (43 before travel, 43 at return, 18 one month after travel). We extracted the whole RNA, performed retrotranscription and sequenced the cDNA (MiSeq 2x300bp). The reads were mapped to the reference operational taxonomic units (OTUs) and species/strains using the 16S Greengenes and 23S SILVA databases. We found that the occurrence of diarrhea during the travel was associated with a higher relative abundance of Prevotella copri before departure and after return. The composition of microbiota, before travel as well as at return, was not correlated with the acquisition of MRE. However, the clearance of MRE one month after return was linked to a specific pattern of bacterial species that was also found before and after return. In conclusion, we found specific OTUs associated to a higher risk of diarrhea during a stay in tropical regions and to a faster clearance of MRE after their acquisition.
Tracing the accumulation of in vivo human oral microbiota elucidates microbial community dynamics at the gateway to the GI tract
Authors: Jinfeng Wang, Zhen Jia, Bing Zhang, Lei Peng, Fangqing Zhao
Journal: Gut (2019)

With great interest we read the article by Gaiser et al 1 that enrichment of oral bacterial taxa in pancreatic cancer highlights the role of oral microbiota. Not coincidentally, the presence of Fusobacterium nucleatum in paired saliva and colon samples of the patients with colorectal cancer has been reported,2 3 raising interest in whether disease starts in the mouth or in the intestine.4–6 Another reason people are interested in oral microbes is their potentials serving as biomarkers for systemic diseases.3 7–9 

In this study, we examined how long the collapsed bacterial community can recover to its initial state when suffering from disturbance and whether oral microbes have sufficient robustness to serve as biomarkers. We longitudinally tracked the re-assembling process of human oral biofilms after clinical scaling. Paired saliva and dental plaque samples were collected from nine subjects at 11 time points (figure 1A and online supplementary figure S1). The 16S rRNA V3–V4 regions of 169 samples were amplified and sequenced, and the generated reads were analysed using QIIME.10 

### Supplementary data

[gutjnl-2019-318977supp001.pdf] 



Figure 1 
Longitudinal dynamics of in vivo human oral microbiota. (A) Overview of the study design and sample collection. (B) The alpha diversity of the dental plaque and salivary microbiota over time. The shadow around the line shows a 95% CI. (C) The Bray-Curtis distance calculated at the operational taxonomic unit (OTU) level across individual microbiota of the same time point. (D–E) The Bray-Curtis distance between microbiota of each time point and pre . Significance was measured using …
Time before return to play for the most common injuries in professional football: a 16-year follow-up of the UEFA Elite Club Injury Study
Authors: Jan Ekstrand, Werner Krutsch, Armin Spreco, Wart van Zoest, Craig Roberts, Tim Meyer, Håkan Bengtsson
Journal: British Journal of Sports Medicine (2019)

The objective was to describe the typical duration of absence following the most common injury diagnoses in professional football.Injuries were registered by medical staff members of football clubs participating in the Union of European Football Association Elite Club Injury Study. Duration of absence due to an injury was defined by the number of days that passed between the date of the injury occurrence and the date when the medical team allowed the player to return to full participation. In total, 22 942 injuries registered during 494 team-seasons were included in the study.The 31 most common injury diagnoses constituted a total of 78 % of all reported injuries. Most of these injuries were either mild (leading to a median absence of 7 days or less, 6440 cases = 42%) or moderate (median absence: 7-28 days, 56% = 8518 cases) while only few (2% = 311 cases) were severe (median absence of >28 days). The mean duration of absence from training and competition was significantly different (p < 0.05) between index injuries and re-injuries for six diagnoses (Achilles tendon pain, calf muscle injury, groin adductor pain, hamstring muscle injuries and quadriceps muscle injury) with longer absence following re-injuries for all six diagnoses CONCLUSIONS: The majority of all time loss due to injuries in professional football stems from injuries with an individual absence of up to 4 weeks. This article can provide guidelines for expected time away from training and competition for the most common injury types as well as for its realistic range.
SAT0427 RISK OF MALIGNANCIES IN PATIENTS WITH GOUT: A POPULATION-BASED COHORT STUDY
Authors: Oh Chan Kwon, Hyun Ah Lee, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Ji Seon Oh, Yong-Gil Kim
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Gout is a chronic disease characterized by deposition of monosodium urate crystals. Comorbidities including hypertension, chronic kidney disease, obesity, diabetes and cardiovascular diseases are common in patients with gout. In contrast to these well-known comorbidities, little is known about the risk of malignancies in patients with gout. <h3>Objectives:</h3> To investigate the risk of malignancies in patients with gout, compared with general population. <h3>Methods:</h3> We conducted a retrospective cohort study using Korean National Health Insurance Service-Medical check-up Cohort Database, which composed of qualified individuals as of 2002 in the age of 40-79 in 2002-2003 who received general medical check-up (Approximately 510,000). We enrolled patients newly diagnosed with gout, based on the diagnostic code and relevant medication history, who were between 40 and 65 years of age at the time of diagnosis between 2003 and 2007 (we washed out first year for newly detected cases). The gout patients (case group) were matched by 1:2 propensity score matching using confounding variables (age, sex, income group, region of residence, smoking status, alcohol intake, exercise habit, comorbidities including diabetes mellitus, hypertension and dyslipidemia, body mass index, blood pressure, serum glucose level, total cholesterol, and hemoglobin) and survival analysis was performed to estimate the risk of malignancy. <h3>Results:</h3> A total of 4991 cases and 419992 controls were identified. The prevalence of Gout was 4991 (1.17%, male 4093 (82.01%); female 898 (17.99%)). During a mean follow-up of 12 years, malignancy was newly diagnosed in 30262 patients (7.12% of the total cohort). Gout was associated with increased risk of malignancy in the multivariable Cox proportional hazard regression analysis before propensity score matching (hazard ratio (HR) 1.248, 95% confidence interval (CI) 1.130-1.379, p&lt;0.001), as well as after matching (HR 1.369, 95% CI 1.209-1.549, p&lt;0.001). <h3>Conclusion:</h3> A total of 4991 cases and 419992 controls were identified. The prevalence of Gout was 4991 (1.17%, male 4093 (82.01%); female 898 (17.99%)). During a mean follow-up of 12 years, malignancy was newly diagnosed in 30262 patients (7.12% of the total cohort). Gout was associated with increased risk of malignancy in the multivariable Cox proportional hazard regression analysis before propensity score matching (hazard ratio (HR) 1.248, 95% confidence interval (CI) 1.130-1.379, p&lt;0.001), as well as after matching (HR 1.369, 95% CI 1.209-1.549, p&lt;0.001). <h3>References</h3> Not applicable <h3>Disclosure of Interests:</h3> None declared
Abstract 17298: Body Awareness but Not Interoceptive Awareness is Associated With Better Heart Failure Self-Management
Authors: Anton Vehovec, Mary Dolansky, Richard Josephson, Joel Hughes
Journal: Circulation (2018)

Introduction: Self-management is important for individuals with heart failure HF to prevent the worsening of the disease and improve quality of life. Self-management includes maintenance, symptom perception, and symptom management. Interoception which includes interoceptive awareness and body awareness are possible mechanisms to explain why patients with HF struggle with self-management. Interoceptive awareness is the objective ability to feel visceral stimuli and use it to inform a decision. Body awareness is the subjective rating of their ability to feel and understand their body. The purpose of this cross sectional descriptive study was to determine if there is an association between interoception and HF self-management and if there are moderating effects of influencing factors on the relationships between interoception and HF self-management. Methods: A total of 100 individuals with heart failure were recruited from a heart failure clinic. Participants answered questionnaires, completed a cognitive test, and the heart beat perception task. Multivariate linear regression was used to test the effect of interoception variables on self-management variables while controlling for anxiety, depression, attention, comorbidities, and rumination. Moderation models for each combination of interoception variables and influencing factors for each outcome were tested. Results: The only significant effect between interoception on a self-management variable was between body awareness and symptom perception (b=.162, p&lt;.05). There were only two significance moderation models. The first was body awareness and comorbidities on symptom management where there was only a positive significant effect of body awareness on symptom management at low values of comorbidities (&lt;2.63). The second moderation model was body awareness and attention on symptom management where there was only a positive significant model at high levels of attention (&gt;90.4). Conclusion: Interoceptive awareness did not have a significant moderation model on any self-management variables. Higher body awareness is significantly associated with better maintenance and symptom management.
Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65 years or older: a nationwide population-based cohort study
Authors: Christian Fynbo Christiansen, Reimar Wernich Thomsen, Morten Schmidt, Lars Pedersen, Henrik Toft Sørensen
Journal: Intensive Care Medicine (2019)
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
Authors: Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay, Jenna M. Voutsinas, Qian Wu, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle
Journal: Blood (2019)